US/UK/Canada

Share

About Us

Mertiva AB (former Diamyd Medical) primarily consists of holdings in liquid assets and holdings in Protein Sciences Corporation and Mercodia AB. Mertiva (former Diamyd Medical) shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC Markets and the Bank of New York Mellon (PAL).

Pick a time period -
Tags ( Active)

Diamyd Medical limits further investment in the diabetes vaccine

Diamyd Medical AB has decided to allocate a maximum of SEK 30 million over three years for the development of the diabetes vaccine Diamyd®.Diamyd Medical’s liquid assets and short term investments amounted to SEK 380 million as of August 31, 2012. The Board has decided to allocate up to SEK 30 million of these for the further development of the diabetes vaccine Diamyd® over the next three years. The development activities are gathered in the subsidiary Diamyd Therapeutics. The diabetes vaccine Diamyd® is based on the GAD65 protein and is being developed for the treatment and prevention of

Diamyd reports initial results from European Phase III trial in patients newly diagnosed with type 1 diabetes

Diamyd Medical AB reports that results from its European Phase III study with the antigen-based therapy Diamyd® did not meet the primary efficacy endpoint of preserving beta cell function at 15 months, as measured by meal stimulated C-peptide, in newly diagnosed type 1 diabetes patients.In Diamyd Medical’s European Phase III study in recently diagnosed type 1 diabetes patients, 10 to 20 years old, the antigen-based therapy, Diamyd®, did not show a statistically significant preservation of beta cell function after 15 months of follow-up compared to placebo, although a small positive effect

Bulletin from Annual General Meeting: One of the most significant years in Diamyd’s history

At Diamyd Medical’s Annual General Meeting on December 9, Elisabeth Lindner, President and CEO of Diamyd, said that the past year was one of the most significant years in the history of the company and that the foundation has been laid upon which a new Swedish pharmaceutical company can be built.“I am very pleased that we continued to deliver according to plan in the past year,” says Elisabeth Lindner, President and CEO of Diamyd Medical. “Following an eventful year, we will now continue to develop Diamyd into a new Swedish pharmaceutical company.” In addition to the signing of a

Summons to the Annual General Meeting of Diamyd Medical AB

The shareholders of Diamyd Medical AB (publ) are hereby summoned to the Annual General Meeting on Thursday December 9, 2010 at 3.00 p.m. at the IVA Conference Center, Grev Turegatan 16 (Wallenberg auditorium) in Stockholm, Sweden.AttendanceShareholders who wish to attend the meeting must be recorded in the register of shareholders held by Euroclear Sweden AB by Friday, December 3, 2010 and must notify the Company of their intention to attend the Meeting by mail to Diamyd Medical, Karlavägen 108, SE-115 26 Stockholm, by e-mail to investor.relations@diamyd.com or on the Company’s website,

Diamyd divides operations into two business areas; Diabetes and Pain

In her comments in today's year end report, Elisabeth Lindner, President and CEO of Diamyd Medical, states that the company has decided to divide its operations into two business areas beginning with the new 2010/2011 fiscal year; Diabetes and Pain.The Diabetes business area consists of the antigen-based candidate drug Diamyd® for the treatment and prevention of autoimmune diabetes. The Pain business area consists of development projects that use the Company's proprietary NTDDS (Nerve Targeting Drug Delivery System) platform to administer drugs directly to the nervous system to treat pain.

Diamyd on the threshold of a new era

In her comments in today's quarterly report, Elisabeth Lindner, President and CEO of Diamyd Medical, notes that a new chapter has begun in the Company’s history with last week’s agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc., to develop and commercialize the Diamyd® diabetes therapy."We will realize the plan to bring Diamyd® to the market in the Nordic countries ourselves and have negotiated exclusivity for this region," says Elisabeth Lindner, President and CEO of Diamyd Medical. "The Nordic market is a prestige market for type 1 diabetes in that the Nordic countries have the

Quarterly Report III 09/10

Third quarter report for Diamyd Medical AB (publ.), fiscal year 2009/2010 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDYThird quarter March 1, 2010 – May 31, 2010 · Group net sales for the third quarter was MSEK 1.3 (0.2) · Loss before tax for the third quarter was MSEK -30.9 (-26.2) · Earnings per share after dilution for the third quarter were SEK -1.1 (-1.2) Period September 1, 2009 – May 31, 2010 · Group net sales for the period was MSEK 2.8 (1.1) · Loss before tax for the period was MSEK -75.3 (-52.1) · The Group’s liquid assets amounted to

Diamyd Medical Signs Agreement for Diabetes Therapy

Diamyd Medical AB has signed an agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), a Johnson & Johnson company, to develop and commercialize the Diamyd® diabetes therapy.The agreement relates to the development and world-wide commercialization of the GAD65 antigen-based therapy (Diamyd®) for the treatment and prevention of type 1 diabetes and associated conditions.OMJPI will make an upfront payment of USD 45 million, and under the terms of the agreement, Diamyd has the potential to receive additional development and sales milestone payments of up to USD 580 million, as

Diamyd® vaccine approved for studies in children down to 3 years of age in the US

Diamyd Medical reports today that the United States Food and Drug Administration (FDA) has approved the experimental use of Diamyd® vaccine in children as young as 3 years of age in the TrialNet GAD study, enrolling 126 new onset type 1 diabetes patients in North America.The TrialNet GAD study, conducted by an international network of leading pediatric and adult endocrinologists and immunologists, has previously enrolled new onset type 1 diabetes patients from 16 to 45 years of age but is now allowed by the FDA to enroll and administer the Diamyd® vaccine to children as young as 3 years of

Diamyd close to important milestone

Diamyd Medical announces today that 90 percent of the total 320 children and adolescents with type 1 diabetes due to participate in the company’s European Phase III study with the diabetes vaccine Diamyd® have now been included and have received injections of Diamyd® or placebo. The company expects all participants to have been included in the study by November 2009.Diamyd Medical is conducting a global Phase III program with the diabetes vaccine Diamyd® comprising a study in nine countries in Europe and a study in the US. In each study 320 children and adolescents aged 10-20 newly

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media